SCHEMBL5994334

SCHEMBL5994334

CCOC(=O)C(Cc1ccc(OCCc2ccc(NC(=O)OC)cc2)cc1)OCC

nearest known ligand 0.53

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 15/20 0.53
PPARG P37231 12/20 0.53
PPARD Q03181 4/20 0.47
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
FAAH O00519 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5992972 1.00 PPARA (0.53) PPARAPPARGPPARDNPC1RAB9A
SCHEMBL5991875 0.90 PPARA (0.66) PPARAPPARGPPARD
SCHEMBL5388906 0.90 PPARA (0.60) PPARAPPARGPPARD
SCHEMBL5991816 0.90 PPARA (0.60) PPARAPPARGPPARD
SCHEMBL7860142 0.89 PPARA (0.47) PPARAPPARGPPARDNPC1RAB9A
SCHEMBL5991942 0.89 FAAH (0.54) PPARAPPARGPPARDNPC1RAB9A
SCHEMBL5993607 0.89 FAAH (0.54) PPARAPPARGPPARDNPC1RAB9A
SCHEMBL5991668 0.88 PPARA (0.53) PPARAPPARGPPARD
SCHEMBL5991661 0.88 PPARA (0.53) PPARAPPARGPPARD
SCHEMBL5992652 0.88 PPARA (0.52) PPARAPPARGPPARDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060173204-A1 New 3-aryl propionic acid derivatives and analogs ANDERSSON KJELL 2006-08-03 US disclosed
US-20040229949-A1 New 3-aryl propionic acid derivatives and analogs ANDERSSON KJELL (SE) 2004-11-18 US disclosed
US-6630600-B1 Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. ASTRAZENECA AB (SE) 2003-10-07 US disclosed
EP-1084102-B1 NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS ASTRAZENECA AB (SE) 2003-10-01 EP disclosed
EP-1084102-A1 NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS AstraZeneca AB (SE) 2001-03-21 EP disclosed
WO-1999062871-A1 NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS ASTRAZENECA AB (SE) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229949-A1 New 3-aryl propionic acid derivatives and analogs GPR119, INSR, IRS1 PPARA 11/4885PPARG 22/4885PPARD 8/4885
US-20060173204-A1 New 3-aryl propionic acid derivatives and analogs GPR119, INSR, IRS1 PPARA 11/4885PPARG 22/4885PPARD 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.